Microbiota-metabolite axis in endometriosis: Pathogenic mechanisms and clinical implications.
Growing evidence highlights the role of microbiota, including those of the gut, reproductive tract, and endometrial tissue, as critical functional drivers in the pathogenesis of endometriosis (EM). Studies have revealed …
Published: April 25, 2026, midnight
Pathogenesis of Adenomyosis: An Integrated Review of Cellular Origins, Molecular Mechanisms, and Intersecting Diseases.
Adenomyosis is a prevalent disorder of the archimetra, historically conflated with endometriosis but possessing a unique pathobiological trajectory. This review synthesises current molecular evidence to propose a unified mechanistic framework …
Published: April 14, 2026, midnight
Gesynta Pharma Doses First Patient in Phase 2 Trial of Non-Hormonal, Non-Opioid Endometriosis Treatment - Femtech Insider
Gesynta Pharma Doses First Patient in Phase 2 Trial of Non-Hormonal, Non-Opioid Endometriosis Treatment Femtech Insider
Published: April 1, 2026, 11:54 a.m.
Gesynta Pharma Doses First Patient in Phase 2 Trial of Non-Hormonal, Non-Opioid Endometriosis Treatment - femtechinsider.com
Gesynta Pharma Doses First Patient in Phase 2 Trial of Non-Hormonal, Non-Opioid Endometriosis Treatment femtechinsider.com
Published: April 1, 2026, 11:54 a.m.
Clinical and endocrine effects of pharmacological therapy in endometriosis: a systematic review and meta-analysis.
Endometriosis, PCOS, adenomyosis, and dysmenorrhea are major illnesses. Hormonal as well as non-hormonal treatments were evaluated for COCs, progestins, GnRH analogues, LNG-IUS, relugolix, and adjunctive therapies. These treatments resulted in …
Published: April 1, 2026, midnight
Hope Medicine Doses First Patient in Phase III Trial of Non-Hormonal Endometriosis Treatment - Femtech Insider
Hope Medicine Doses First Patient in Phase III Trial of Non-Hormonal Endometriosis Treatment Femtech Insider
Published: March 30, 2026, 1:56 p.m.
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - BioSpace
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis BioSpace
Published: March 23, 2026, 12:47 p.m.
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - PR Newswire
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis PR Newswire
Published: March 23, 2026, 11:30 a.m.
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - Digital Journal
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis Digital Journal
Published: March 18, 2026, 12:41 p.m.
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - ACCESS Newswire
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis ACCESS Newswire
Published: March 18, 2026, 10:13 a.m.